UIC - DDN - Jay Goldstein, MD

My clinical interests include the practice of general gastroenterology. I have a special interest in caring for patients with esophageal diseases including gastro-esophageal reflux diseases (GERD) and diseases of the upper gastrointestinal tract such as peptic ulcer disease. I also have an interest in irritable bowel syndrome.

My research interests include evaluating and optimizing the diagnostic and therapeutic approaches to patients with GERD and peptic ulcer disease. I have a special interest in understanding how drugs such as non-steroidal anti-inflammatory agents (NSAIDs) cause ulcers in the stomach and small intestine. I have participated in many trials comparing the safety profile of NSAIDs vs. the newer drugs known as COX2 specific inhibitors [e.g. Celecoxib (Celebrex®), rofecoxib (Vioxx®))]. Over the past 10 years I have taken a strong interest and have conducted studies in the area of so called “outcomes research.”

Silverstein FE, Faich G, Goldstein JL , Simon L, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson W, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis S. The CLASS study: A randomized controlled trial. JAMA 284(10):1247-1255, 2000.
Goldstein JL , Correra P, Zhao WW, Burr AM, Hubbard RC, Verburg K, Geis, GS. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared with naproxen in patients with arthritis. AJ G , 96(4):1019-27, 2001.
Burke TA, Zabinski RA, Pettitt D, Maniadakis N, Maurath CJ, Goldstein JL . A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis. Pharmacoeconomics, 19, Suppl. 1:33-47, 2001.
Campbell DR, Haber MM, Sheldon E, Collis C, Lukasik N, Huang B, Goldstein JL . Effect of H. pylori status on healing of gastric ulcer in patients continuing to take nonsteroidal antiinflammatory agents and treated with lansoprazole or ranitidine. AJG, 97(9): 2208-2214, 2002.
Johnson DA, Benjamin SB, Vakil NB, Goldstein JL , Lamet M, Whipple J, D'Amico D, Hamelin B. Esomeprazole once daily for six months is effective therapy for maintenance of healing of erosive esophagitis and control of GERD symptoms: A randomized, double-blind, placebo-controlled, study of efficacy and safety. AJG, 96(4):27-34, 2001.
Gandhi, SK, Reynold MW, Boyer G, Goldstein JL . Recurrence and malignancy rate in a benign colorectal neoplasm patient cohort: results of five year follow-up in managed care environment. Am J Gastro 96 (6): 2761-2767, 2001.
Pettitt D, Goldstein JL , McGuire A, Schwartz S, Burke T, Maniadakis N. Overview of the arthritis cost consequence evaluation system (ACCES):A pharmoeconomic model for celecoxib. Rheumatology; 39(Suppl. II). 33-42, 2000.
Harris SI, Kuss, M, Hubbard RC, Goldstein JL . Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral COX-2 specific inhibitor, as compared to nonselective NSAIDs. Clinical Therapeutics 23 (9): 1422-1428, 2001.
Goldstein JL , Malik P, Larson LR, Yamashita BD, Fain JM, Schumock GT. Low molecular weight heparin versus unfractionated heparin in the colonoscopy peri-procedure period: A cost modeling study. AJG, 96(8):2360-2366, 2001.
Rabeneck L, Wristers K, Goldstein JL , Eisen G, Dedhiya SD, Burke TA. Reliability, validity and responsiveness of severity of dyspepsia assessment (SODA) in a randomized clinical trial of selective and nonselective NSAID therapy. AJG, 97 (1): 32-39, 2002
Goldstein JL , Eisen GM, Burke TA, Pena B, Lefkowith J. Assessing dyspepsia from the patients' perspective: a comparison of celecoxib with diclofenac. APT, 16: 819-827, 2002
Goldstein JL, Bello AE, Fort JG. COX-2 specific inhibitors and upper gastrointestinal tolerability in osteoarthritis patients receiving concomitant low-dose aspirin: A pooled analysis of 2 trials. Submitted to the Journal of Rheumatology. August, 2003.
Goldstein JL , Kivitz AJ, Verburg KM, Recker DP, Palmer RC, Kent JD. A comparison of the upper gastrointestinal mucosal effects of valdecoxib, naproxen and placebo in healthy elderly subjects. Alimentary Pharmacology and Therapeutics 2003: 18(1) 125-132.
McDonald TM, Morant SV, Goldstein JL , Burke TA, Pettitt D. The incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs and older, non-specific nonsteroidal anti-inflammatory drugs. GUT 2003:52: 1265-1270.
Morant S, Pettitt D, McDonald TM, Burke TA, Goldstein JL. Application of a propensity score to assess the incidence of gastrointestinal hemorrhage in users of Coxibs, Meloxicam and non-selective nonsteroidal anti-inflammatory drugs. Submitted to Journal of Clinical Epidemiology, 2003.
Sturkenboom MCJM, Burke, TA, Dieleman JP, Tangelder MJD, Lee F, Goldstein JL. Underutilisation of protective strategies in patients receiving NSAIDs. Rheumatology June, 2003; 42 (Suppl 3) iii23-iii31.
Rabeneck L, Goldstein JL, Wong JM, Vu A, Mayne TJ. Valdecoxib is associated with improved dyspepsia-related health compared with non-selective NSAIDs in patients with osteoarthritis and rheumatoid arthritis. Submitted to the Archives of Internal Medicine. July, 2003.
Singh G, Fort JG, Goldstein JL , Levy RA, Hanrahan PS, Bello AE, Andrade-Ortega L, Wallemark C, Agrawal N, Eisen G, Stetson W, Triadafolpoulis G for the SUCCESS-I Investigators. Efficacy and upper gastrointestinal safety of celecoxib compared to naproxen and diclofenac in patients with osteoarthritis: Results from a large international, randomized double-blind, controlled clinical trial. Submitted to the NEJM. July, 2003.
Goldstein JL. Celecoxib is associated with reduced chronic gastrointestinal (GI) blood loss relative to nonsteroidal anti-inflammatory drugs (NSAIDs). Manuscript in preparation.
Sturkenboom MCJM, Burke TA, Tangelder M, Dielman JP, Walton S, Goldstein JL. Adherence with co-administered preventative therapies associated with the use of NSAID. In press, Alimentary Pharmacology and Therapeutics. July, 2003.
Simon LS, Strand V, Faich G, Pincus T, Goldstein JL , Silverstein F, Whelton A, Machuch R. The CLASS Trial: The entire dataset. Manuscript in preparation
Goldstein, JL, Zhao, SZ, Burk, TA, Palmer R, von Allmen, H, Henderson SC. Incidence of Outpatient physician claims for upper gastrointestinal (UGI) symptoms among new users of celecoxib, ibuprofen, and naproxen in a U.S. insured population. In press, American Jouranal of Gastroenterology, 2003.